JP2023540453A5 - - Google Patents

Info

Publication number
JP2023540453A5
JP2023540453A5 JP2023510359A JP2023510359A JP2023540453A5 JP 2023540453 A5 JP2023540453 A5 JP 2023540453A5 JP 2023510359 A JP2023510359 A JP 2023510359A JP 2023510359 A JP2023510359 A JP 2023510359A JP 2023540453 A5 JP2023540453 A5 JP 2023540453A5
Authority
JP
Japan
Prior art keywords
freeze
bacteria
drying step
dried
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023510359A
Other languages
English (en)
Japanese (ja)
Other versions
JP7809362B2 (ja
JP2023540453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/046055 external-priority patent/WO2022036298A1/en
Publication of JP2023540453A publication Critical patent/JP2023540453A/ja
Publication of JP2023540453A5 publication Critical patent/JP2023540453A5/ja
Application granted granted Critical
Publication of JP7809362B2 publication Critical patent/JP7809362B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023510359A 2020-08-14 2021-08-15 凍結乾燥生ボルデテラワクチン Active JP7809362B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066020P 2020-08-14 2020-08-14
US63/066,020 2020-08-14
PCT/US2021/046055 WO2022036298A1 (en) 2020-08-14 2021-08-15 Lyophilized live bordetella vaccines

Publications (3)

Publication Number Publication Date
JP2023540453A JP2023540453A (ja) 2023-09-25
JP2023540453A5 true JP2023540453A5 (enExample) 2024-06-27
JP7809362B2 JP7809362B2 (ja) 2026-02-02

Family

ID=80247370

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023510359A Active JP7809362B2 (ja) 2020-08-14 2021-08-15 凍結乾燥生ボルデテラワクチン

Country Status (12)

Country Link
US (1) US20230173053A1 (enExample)
EP (1) EP4196155A4 (enExample)
JP (1) JP7809362B2 (enExample)
KR (1) KR20230051186A (enExample)
CN (1) CN116322756A (enExample)
AU (1) AU2021325149A1 (enExample)
BR (1) BR112023002549A2 (enExample)
CA (1) CA3187934A1 (enExample)
CL (1) CL2023000451A1 (enExample)
CO (1) CO2023002823A2 (enExample)
MX (1) MX2023001905A (enExample)
WO (1) WO2022036298A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2215033C2 (ru) * 2001-06-27 2003-10-27 Научно-исследовательский институт микробиологии МО РФ Способ получения концентрата микробных клеток в производстве чумных вакцин
EP1708747A2 (en) * 2004-01-15 2006-10-11 Intervet International BV Non-animal origin stabilizers and processes for producing the same
US9119804B2 (en) 2006-03-10 2015-09-01 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
AR097762A1 (es) * 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
EP4541809A3 (en) 2016-03-29 2025-06-25 Institut Pasteur de Lille Mutant bordetella strains and methods of use
RU2709657C2 (ru) * 2017-08-07 2019-12-19 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) Способ лиофильного высушивания аттенуированных бактерий B. pertussis, аттенуированная бактерия B. pertussis, штамм аттенуированных бактерий B. Pertussis, вакцина, лиофилизированный вакцинный препарат
WO2020049133A1 (en) 2018-09-05 2020-03-12 National University Of Singapore Adenylate cyclase catalytic domain deficient bordetella strains

Similar Documents

Publication Publication Date Title
Mirtaleb et al. Potential therapeutic agents to COVID-19: An update review on antiviral therapy, immunotherapy, and cell therapy
JP2018199695A5 (enExample)
JP2019517828A5 (enExample)
SA521430813B1 (ar) لقاح وحدات فرعية لعلاج عدوى الجهاز التنفسي أو الوقاية منها
CO6460761A2 (es) Vacuna viva modificada de mycoplasma bovis mejorada, métodos de producción de vacunas vivas de mycoplasma bovis, vacunas de combinación y métodos de tratamiento
WO2010036938A3 (en) Nanoemulsion therapeutic compositions and methods of using the same
JP2016539946A5 (enExample)
JP2016509011A5 (enExample)
MX388743B (es) Conjugados oligonucleótido-péptido.
HRP20210780T1 (hr) Pripravci koji sadrže bakterijske sojeve
ZA202203363B (en) Immunogenic compositions
JP2023540453A5 (enExample)
WO2021205026A3 (en) Pharmaceutical composition for treatment of enveloped dna or rna virus induced infections and disorders
WO2022011271A3 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
RU2017144216A (ru) Антибактериальные композиции
WO2017140683A3 (en) Streptococcus uberis extract as an immunogenic agent
CN106266589A (zh) 一种治痨病的配方
Selvamuthu et al. Antibacterial activity of methanolic extract of Ludwigia perennis leaves
JP2017525726A5 (enExample)
Park et al. A case of pneumonia and parapneumonic effusion caused by Streptococcus parasanguinis
Ranganathan et al. COVID-19: a novel strain challenging the human race
Mahu et al. Weakly hemolytic Brachyspira hyodysenteriae strains in pigs
Ren et al. Arbuscular mycorrhizal colonization modulates watermelon root secretion of p-coumaric acid which up-regulates ClPR_3 gene expression
Tehrani et al. Pantoea Agglomerans, A Plant Pathogen Causing Human Disease
TH135890A (th) วัคซีนเชื้อเป็นที่ได้รับการดัดแปรปรับปรุงของ Mycoplasma bovis, วิธีการผลิตวัคซีน เชื้อเป็นที่ได้รับการดัดแปรของ Mycoplasma bovis, วัคซีนรวม และวิธีการรักษา